

TRIDOCOSAHEXANOÍNA-AOX®

30 YEARS

PROVIDING  
SCIENTIFIC INNOVATION  
IN HEALTH CARE

1995 – 2025



BRUDYLAB®

## About us

BRUDY is a pioneering biotechnology company in Medical Nutrition. We believe in high-quality clinical research and are driven by our innovative spirit in the field of omega-3 fatty acids, particularly Docosahexaenoic Acid (DHA) and its impact on human health.

Our goal is to improve the quality of life for everyone and contribute to the treatment of diseases associated with oxidative stress and inflammation.



## Our track record

BRUDY has been committed to researching and developing innovative DHA-based products since 1995. Our multidisciplinary team focuses on creating top-quality products. Our approach merges science and state-of-the-art techniques, providing tailored solutions with an ongoing commitment to excellence and innovation.

We have invested more than €10 million in research projects throughout our history and hold three international patents<sup>1-3</sup> on the use of our DHA-enriched triglyceride, Tridocosahecanoína-AOX®.


We meet the highest quality standards and have repeatedly provided optimal bioactivity, hence positioning us as global leaders in this field.

BRUDYLAB has focused on marketing our proprietary products with Tridocosahecanoína-AOX® as the main ingredient in food supplements, food for special medical purposes as well as cosmetic products on a national and international level since 2010.

## DHA – an essential omega-3 for health

DHA is a very long-chain (C22:6) polyunsaturated fatty acid, an essential omega-3 for cell membrane structure and function.

### Fatty acid concentration found in human tissues<sup>4</sup>



## BRUDY worldwide

● BRUDYLAB ● BRUDYTECHNOLOGY



## Health benefits of DHA acknowledged by the European Commission<sup>5</sup>


HEALTH BENEFITS OF DHA APPROVED BY THE EUROPEAN COMMISSION	CONSUMERS SHOULD BE INFORMED THAT BENEFITS ARE OBTAINED WITH THE INTAKE OF:
DHA (and DHA + EPA) contributes to normal heart function.	250 mg/day of DHA (EU 432/2012). For adults. EFSA Journal 2014;12(10):3840. For children aged 2 to 18.
DHA contributes to normal vision.	
DHA contributes to normal brain function.	
DHA contributes to normal visual development in children up to 12 months.	100 mg/day of DHA (EU 440/2011).
Maternal intake of DHA contributes to normal visual development of the foetus and of breastfed infants.	(Pregnant and breast-feeding women) 200 mg/day of DHA in addition to the 250 mg/day daily intake for adults (EU 440/2011).
Maternal intake of DHA contributes to normal brain development of the foetus and of breastfed infants.	
DHA (or DHA + EPA) helps maintain normal triglyceride levels in the blood.	2 g/day of DHA or DHA + EPA. Do not exceed 5 g/day of combined intake (EU 536/2013).
DHA and EPA help reduce blood pressure.	3 g/day of DHA or DHA + EPA. Do not exceed 5 g/day of combined intake (EU 536/2013).

EU Regulatory Consultations at: [www.eur-lex.europa.eu](http://www.eur-lex.europa.eu) (search by year and regulation no. mentioned in the right-hand table column)

# What is Tridocosahexanoína-AOX®?


A DHA-enriched source developed by BRUDY as highly purified and structured re-esterified triglyceride to ensure bioavailability and biological efficacy.

## Tridocosahexanoína-AOX® synthesis in 3 steps:




	European legislation <sup>6</sup>	GOED	IFOS	Brudy's batch*
<b>Purity, safety and cleanliness</b>				
PCBs	200 ng/g	90 ng/g	<=45 ppb	<15 ng/g
Dioxins	1.75 pg/g	1.75 pg/g	<= 1 ppt	<0.4 pg/g
Dioxins and similar PCBs	6 pg/g	3 pg/g	<= 1.5 ppt	<0.5 pg/g
<b>Heavy metals</b>				
Mercury (Hg)	0.5 ppm	0.1 ppm	<= 0.1 ppm	<0.005 ppm
Lead (Pb)	0.1 ppm	0.05 ppm	<= 0.1 ppm	<0.02 ppm
Arsenic (As)	-	0.1 ppm	<= 0.1 ppm	<0.05 ppm
Cadmium (Cd)	0.1 ppm	0.1 ppm	<= 0.1 ppm	<0.05 ppm
<b>Stability</b>				
Acid value	-	-	<=3 mg KOH/g	0.1 mg KOH/g
Peroxide	-	-	<=5 meq/kg	2-4 meq O2/kg
Anisidine	-	-	<=20	4-10 U.A.

\*Each batch of oil is analysed by Eurofins Analytics



## What happens in the body?




## Proven short- and long-term bioavailability<sup>7, 8</sup>


In the short term, supplementation with Tridocosahexanoína-AOX® increases DHA levels in cell membranes, suggesting **efficient absorption** and **quick incorporation** into tissues.

From the outset, a dependent relationship between increased DHA and reduced arachidonic acid (ARA) levels was observed.

In the long term, ongoing supplementation keeps DHA levels high.



n = 54 healthy volunteers  
5 groups: placebo and increasing doses of Tridocosahexanoína-AOX®  
Duration = 1 month



n = 73 HIV+ patients  
Control group (n = 38) without supplementation  
Experimental group (n = 35) with 4 g/day of Tridocosahexanoína-AOX®  
Duration = 1 year



## Patented antioxidant activity of Tridocosahexanoína-AOX®

Our analyses of human cell cultures revealed that, with Tridocosahexanoína-AOX®, cell membranes **increase glutathione synthesis by 200% to 300%**<sup>9</sup>. This powerful antioxidant, which is essential for regulating internal cellular balance, protects cells from oxidative stress by

neutralising free radicals that can damage cells and cause cell death. Glutathione protects cellular health, and its increase, which is stimulated by Tridocosahexanoína-AOX®, prepares cells to withstand external aggressions.

ARPE-19 RETINAL CELLS CONTROL GROUP CELL CULTURE

ARPE-19 RETINAL CELLS BRUDY TG-DHA CELL CULTURE



GSH: Glutathione

ARA: Arachidonic Acid Omega 6


DHA: Docosahexaenoic Acid Omega 3

200-300% increase of glutathione

Increase in endogenous antioxidant defence capacity

## Bioactivity – our main Gold standard

At BRUDY, we produce clean, pure DHA as bioavailable triglyceride with **bioactivity that mimics human physiology**. Our production process preserves the natural DHA structure, while maintaining the cis double bonds that provide its antioxidant capacity and benefits for the body. Each batch of oil undergoes cellular bioactivity testing to ensure its **antioxidant protection activity (50-60%)**. Unlike other processes, our technology ensures that bioactivity does not only depend on DHA concentration, but also on the preservation of its structure, from oil extraction to the end product.



## Clinical research

At BRUDY, our mission is to back up the benefits of our products with scientific evidence, while always seeking to provide innovative solutions based on current needs. Thus,

we work with national and international experts in several areas, such as ophthalmology, fertility, sports medicine or lipid metabolism disorders.

## Evidence of Tridocosa-hexanoína-AOX® in other therapeutic areas

### CHILD CARE




3 studies

- ✓ Improvement in cognitive and behavioural variables supporting its benefit in children and adolescents with attention deficit hyperactivity disorder (ADHD)
- ✓ Improvements in lung function (FVC and FEV1) and decrease in the number of exacerbations in children with cystic fibrosis


#### Child care<sup>1</sup>

- N = 66 patients aged 6 to 18 with ADHD
- 1000-2000 mg/day of Tridocosa-hexanoína-AOX® (according to weight)
- Duration = 6 months



#### Child care<sup>3</sup>

- N = 22 patients (aged 6 to 18)
- Placebo group = 11 patients
- Supplemented group = 11 patients with 700-2800 mg/day of Tridocosa-hexanoína-AOX® (according to weight)
- Duration = 1 year



### FERTILITY




4 studies

- ✓ Increased antioxidant capacity
- ✓ Decreased DNA fragmentation
- ✓ Increased sperm motility

#### Fertility<sup>4</sup>

- N = 64 subjects undergoing fertility assessment
- Placebo group = 29
- Supplemented group = 35 (1050 mg/day of Tridocosa-hexanoína-AOX®)
- Duration = 10 weeks



## 42 clinical studies + 5 review articles

### Eye care

19 studies

3 review articles



9 studies on Dry eye\*



5 studies Retina + review articles



4 studies on Glaucoma\*



2 studies on Eye inflammation



1 study Topical effect + review article\*\*

### Other therapeutic areas

23 studies

2 review articles



6 studies Sports



3 studies Lipid metabolism disorder + review articles



4 studies Fertility



4 studies Children with ADHD



2 studies Cystic fibrosis



3 studies Neurological disorder



4 studies In vitro techniques

\*Categories shared by one or more studies.  
\*\*Accepted article pending publication

DHA triglyceride concentration  
**70%**

Antioxidant protection  
**50-60%**

Glutathione increase  
**200-300%**

**100%** bioactivity in each batch

**3** patents for Tridocosa-hexanoína-AOX® use

## SPORTS




6 studies

- ✔ Significant protection against oxidative damage resulting from moderate-intense exercise
- ✔ Improved perceptual-motor reaction time
- ✔ It promotes low inflammation concentrations and muscle damage markers, while also decreasing muscle pain


### Sports<sup>6</sup>

- n = 40 healthy sportspeople
- Treatment with 2000 mg/day of Tridocosahexanoína-AOX<sup>®</sup>
- Duration = 3 months




### Sports<sup>1</sup>

- N = 24 professional female football players
- Control group n = 12 placebo
- Supplemented group n = 12 3500 mg/day of Tridocosahexanoína-AOX<sup>®</sup>
- Duration = 4 weeks



### Sports<sup>4</sup>

- n = 15 triathletes
- Supplemented group with 2000 mg/day of Tridocosahexanoína-AOX<sup>®</sup>
- Duration = 10 weeks







## LIPID METABOLISM



3 studies

2 review articles

- ✔ Correction of intrahepatic omega-6/omega-3 imbalance
- ✔ Reduction of intrahepatic oxidative stress: -20.7%
- ✔ Reduction in the expression level of circulating inflammatory markers: IL-1β: -65% | IL-10: -61% | IL-6: -71.63%
- ✔ Deactivation of mouse and human hepatic stellate cell and slowing down of the fibrotic process
- ✔ Significant reduction in portal pressure: -13.4%
- ✔ Reduction in circulating aspartate aminotransferase: -25.7%



### Lipid metabolism<sup>3</sup>

- n = 12 healthy rats and 25 cirrhotic rats
- ½ with placebo and ½ supplemented with Tridocosahexanoína-AOX<sup>®</sup> (500 mg/kg)
- Duration = 2 weeks

# Evidence of Tridocosahecanoína-AOX® in eye care


## DRY EYE SYNDROME




9 studies

- Improved dry eye symptoms
- Reduced inflammation
- Improved tear quantity and quality


**Dry eye disease<sup>1</sup>**  
 • n = 905 patients with dry eye symptoms  
 • 1050 mg/day of Tridocosahecanoína-AOX®  
 • Duration = 3 months



**Dry eye disease<sup>1</sup>**  
 • n = 66 patients (132 eyes)  
 • 1050 mg/day of Tridocosahecanoína-AOX®  
 • Mild-moderate dry eye group > 1 year (n = 30)  
 • ½ suppl. – ½ not suppl.  
 • Healthy control group (n = 36)  
 • ½ suppl. – ½ not suppl.  
 • Duration = 3 months



**Dry eye disease<sup>3</sup>**  
 • n = 61 patients with meibomian gland dysfunction (MGD)  
 • Control group (n = 31) with placebo  
 • Experimental group (n = 30) 1050 mg/day of Tridocosahecanoína-AOX®  
 • Duration = 3 months



## RETINAL/MACULAR DISORDERS




5 studies


2 review articles

- Anti-oedematous effect in addition to conventional treatment of Age-related Macular Degeneration (AMD)
- Significant increase in Macular Pigment Optical Density (MPOD)
- Improved macular sensitivity and macular integrity assessment in Non-Proliferative Diabetic Retinopathy (NPDR)


**Retinal/macular disorders<sup>3</sup>**  
 • n = 77 AMD patients treated with ranibizumab IV  
 • Control group (n = 29) without supplementation  
 • Experimental group (n = 26) 1050 mg/day of Tridocosahecanoína-AOX®  
 • Duration = 36 months



**Retinal/macular disorders<sup>4</sup>**  
 • n = 100 healthy volunteers (200 eyes)  
 • Control group (n = 49) Placebo with lutein  
 • Experimental group (n = 51) 1050 mg/day of Tridocosahecanoína-AOX®  
 • Duration = 3 months



**Retinal/macular disorders<sup>2</sup>**  
 • n = 24 patients with NPDR  
 • Control group (n = 12) without supplement  
 • Experimental group (n = 12) 1050 mg/day of Tridocosahecanoína-AOX®  
 • Duration = 3 months



## GLAUCOMA




4 studies

- Improved visual field indices and progression rate with Tridocosahexanoína-AOX® + citicoline combined
- Improved dry eye symptoms and decrease in lacrimal gland inflammation
- Antioxidant and inflammation-regulating effects as mechanisms related to glaucoma



### Glaucoma<sup>4</sup>

- n = 73 glaucoma patients with controlled IOP
- Control group (n = 17) vitamin C
- Group A (n = 16) 1050 mg/day of Tridocosahexanoína-AOX®
- Group B (n = 20) 326 mg of citicoline
- Group C (n = 20) 1050 mg/day of Tridocosahexanoína-AOX® + 326 mg of citicoline
- Duration = 3 months



### VISUAL FIELD PARAMETERS AT BASELINE AND AFTER 3 MONTHS OF TREATMENT

	Baseline MD (dB)	Month 3 MD (dB)	p Value	Baseline VFI (%)	Month 3 VFI (%)	p Value
Global (mean ± SD)	-8,96 ± 3,91	-8,42 ± 4,29	0,025	77,47 ± 12,83	78,52 ± 13,94	0,096
Vitamin C (mean ± SD)	-8,46 ± 3,70	-8,32 ± 3,87	0,727	78,35 ± 12,97	78,53 ± 13,24	0,871
DHA (mean ± SD)	-9,08 ± 4,07	-8,86 ± 5,07	0,685	78,13 ± 12,83	77,56 ± 15,72	0,719
Citicoline (mean ± SD)	-8,74 ± 3,70	-8,71 ± 4,17	0,957	78,50 ± 12,46	78,90 ± 13,16	0,687
DHA+Citicoline (mean ± SD)	-9,52 ± 4,36	-7,85 ± 4,36	0,001	75,15 ± 13,76	78,90 ± 14,82	0,008

### COMPARISON BETWEEN PRE- AND POST-TREATMENT VISUAL FIELD INDEX SLOPES IN EACH GROUP


	MD Slopes (dB/Month)		p Value	VFI Slopes (%/Month)		p Value
	Pretreatment	Post-Treatment		Pretreatment	Post-Treatment	
Global (mean ± SD)	-0,0613 ± 0,1736	0,0867 ± 0,3092	0,005	-0,1107 ± 0,2781	0,1625 ± 0,8499	0,018
Vitamin C (mean ± SD)	-0,0502 ± 0,1459	0,055 ± 0,2895	0,350	-0,079 ± 0,3665	0,1425 ± 0,8992	0,485
DHA (mean ± SD)	-0,0135 ± 0,1116	0,0295 ± 0,1939	0,733	-0,0509 ± 0,1998	0,0150 ± 0,5971	0,532
Citicoline (mean ± SD)	-0,0624 ± 0,1307	0,1029 ± 0,4504	0,192	-0,1364 ± 0,3151	0,1733 ± 1,2439	0,371
DHA+Citicoline (mean ± SD)	-0,1041 ± 0,2471	0,1383 ± 0,2544	0,006	-0,1557 ± 0,2310	0,2780 ± 0,5661	0,006

MD, mean defect of visual field; dB, decibels; VFI, visual field index; SD, standard deviation; DHA, docosahexanoic acid.

### Glaucoma<sup>1</sup>

- n = 97 patients suffering from dry eye
- Group 1 – Mild-moderate dry eye (n = 30) ½ suppl. – ½ not suppl.
- Group 2 – Primary Open-Angle Glaucoma (POAG) (n = 31) ½ suppl. – ½ not suppl.
- Group 3 – Healthy controls (n = 36) ½ suppl. – ½ not suppl.
- 700 mg/day of Tridocosahexanoína-AOX®
- Duration = 3 months


### IL-6 AND TNF-α IN TEAR SAMPLES FROM THE GLAUCOMA GROUP




### Glaucoma<sup>3</sup>

- n = 47 patients suffering from pseudoexfoliative glaucoma with controlled IOP
- Control group (n = 24) without supplement
- Experimental group (n = 23) 1050 mg/day of Tridocosahexanoína-AOX®
- Duration = 6 months


### CHANGES IN TAC



### CHANGES IN IL-6



### DECREASE IN MDA



## EYE INFLAMMATION




2 studies

- Reduced systemic inflammatory burden
- Antioxidant and anti-inflammatory effect to address the underlying pathophysiological mechanisms of keratoconus

### Eye inflammation<sup>1</sup>

- n = 62 patients
- Group 1 (n = 30) healthy volunteers ½ suppl. – ½ not suppl.
- Group 2 (n = 32) NIU in remission phase ½ suppl. – ½ not suppl.
- 500 mg/day of Tridocosahexanoína-AOX®
- Duration = 3 months


### COMPARISON BETWEEN SUPPLEMENTED NIAU PATIENTS AND UNSUPPLEMENTED NIAU PATIENTS




### Eye inflammation<sup>2</sup>

- n = 34 patients with keratoconus
- Control group n = 15 without supplement
- Supplemented group n = 19 1000 mg/day of Tridocosahexanoína-AOX®
- Duration = 3 months

### PLASMA ANTIOXIDANT PROTECTION



### PLASMA INFLAMMATORY MARKERS



## TOPICAL TREATMENT



1 study


1 review article

- Clinically proven efficiency and safety of cream with Tridocosahexanoína-AOX®

### Topical effect<sup>1</sup>

- n = 60 healthy volunteers (30 contact lens wearers)
- 1 application of cream on the eyelid skin at night
- Duration = 2 weeks

### OSDI – VALIDATION OF THE SYMPTOM QUESTIONNAIRE (Ocular Surface Disease Index)



## References

1. Patent WO 2006120120 A1: Use of docosahexaenoic glycerides for the treatment of tumorous diseases.
2. Patent WO 2004050077 A1: Use of docosahexanoic acid as active substance for the treatment of lipodystrophy .
3. Patent WO 2007/ 071733 A3: Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage.
4. Linda M Arterburn, et al; Distribution, interconversion, and dose response of ω-3 fatty acids in humans; *Am J Clin Nutr* 2006;83(suppl):1467S–76S.
5. List of authorised health claims for docosahexaenoic acid (DHA), as suggested by the EFSA (European Food Safety Authority). REGULATION (EU) no. 432/2012 and REGULATION (EU) no. 440/2011.
6. EC Regulation no. 1881/2006 (19 December 2006) setting maximum levels of contaminants in foodstuffs and amendment no. 1259/2011.
7. Carlos J Contreras; Modification of the oxidative damage in a group of cyclists after consuming docosahexaenoic acid at different doses; Doctoral Thesis, Catholic University of Murcia, 2014.
8. Domingo P, et al., Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study, *Clinical Nutrition* (2017), <http://dx.doi.org/10.1016/j.clnu.2017.05.032>.
9. P. Bogdanov, et al; Docosahexaenoic Acid Improves Endogen Antioxidant Defense in Arpe-19 Cells; *IOVS, ARVO Journals*; May 2008, Vol.49, 5932.

### DRY EYE SYNDROME (DES)

1. Pinazo-Durán MD, et al; Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders; *Clinical Int Aging* 2013; 8:139-148.
2. Galbis-Estrada C, et al; Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surfacedisorder to oral supplement with antioxidants and essential fatty acids; *Clin Int Aging* 2013;8:711-9 \*También en el apartado de GLAUCOMA.
3. Oleňik A, Jiménez-Alfaro I, Alejandre-Alba N, Mahillo-Fernández I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. *Clin Interv Aging*. 2013;8:1133-8. doi: 10.2147/CIA.S48955. Epub 2013 Aug 30. PMID: 24039409; PMCID: PMC3770496.
4. Oleňik A, et al; Effectiveness and tolerability of dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: results of a prospective study; *Clinical Ophthalmology* 2014;8 169–176.
5. Oleňik A, et al; Benefits of Omega-3 fatty acid dietary supplementation on health-related quality of life in patients with Meibomian Gland Dysfunction; *Clinical Ophthalmol* 2014; 8:831-836.
6. Ribelles A, et al; Ocular Surface and Tear Film Changes in Older Women Working with Computers; *BioMed Research International* 2015; Article ID 467039.
7. Galbis-Estrada C, et al; A metabolomic approach to dry eye disorders. The role of oral supplements with antioxidants and omega 3 fatty acids; *Mol Vis*.2015 May 11;21:555-67.
8. Gatell-Tortajada J, et al; Oral supplementation with a nutraceutical formulation containing omega-3 fatty acids, vitamins, minerals, and antioxidants in a large series of patients with dry eye symptoms: results of a prospective study; *Clin Int Aging* 2016; 11:571-578
9. Tellez-Vazquez J, et al; Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study; *Clin Ophthalmol* 2016; 10:617-626. \*Also in the GLAUCOMA Section.

### RETINAL AND MACULAR DISORDERS (RMD)

1. Lafuente M, Ortín L, Argente M, Guindo JL, López-Bernal MD, López-Román FJ, García MJ, Domingo JC, Lajara J. COMBINED

- INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITHDOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results. *Retina*. 2017 Jul;37(7):1277-1286. doi:10.1097/IAE.0000000000001363. PMID: 27787443.
2. Rodríguez González-Herrero ME, Ruiz M, López Román FJ, Marín Sánchez JM, Domingo JC. Supplementation with a highly concentrated docosahexaenoic acid plus xanthophyll carotenoid multivitamin in nonproliferative diabetic retinopathy: prospective controlled study of macular function by fundus microperimetry. *Clin Ophthalmol*. 2018 May 29;12:1011-1020. doi: 10.2147/OPTH.S157635. PMID:29881256; PMCID: PMC5983010.
3. Lafuente M, Ortín L, Argente M, Guindo JL, López-Bernal MD, López-Román FJ, Domingo JC, Lajara J. THREE-YEAR OUTCOMES IN A RANDOMIZED SINGLE-BLIND CONTROLLED TRIAL OF INTRAVITREALRANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA. *Retina*. 2019 Jun;39(6):1083-1090. doi:10.1097/IAE.0000000000002114. PMID: 29474306; PMCID: PMC6553973.
4. Zanón-Moreno V, Domingo Pedrol JC, Sanz-González SM, Raga-Cervera J, Salazar-Corral J, Pinazo-Durán MD. Feasibility Study of a Docosahexaenoic Acid-Optimized Nutraceutical Formulation on theMacular Levels of Lutein in a Healthy Mediterranean Population. *Ophthalmic Res*. 2021;64(6):1068-1076. doi: 10.1159/000509439. Epub 2020 Jun 16. PMID: 32544914; PMCID: PMC8743924.
5. Piñas García P, Hernández Martínez FJ, Aznárez López N, Castillón Torre L, Tena Sempere ME. Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative DiabeticRetinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study. *Antioxidants (Basel)*. 2022 Jan 5;11(1):116. doi: 10.3390/antiox11010116. PMID: 35052620; PMCID: PMC8772895. Reviews:
6. Abreu-González R, Díaz-Rodríguez R, Abreu-Reyes JA. Nutritional supplements with omega 3 in retinal disease: Relationship between volume and concentration in commercial products. *Arch Soc EspOftalmol (Engl Ed)*. 2018 Dec;93(12):592-597. English, Spanish. doi: 10.1016/j.oftal.2018.05.015. Epub 2018 Jul 17. PMID: 30025989.
7. Lafuente M, Rodríguez González-Herrero ME, Romeo Villadóniga S, Domingo JC. Antioxidant Activity and Neuroprotective Role of Docosahexaenoic Acid (DHA) Supplementation in Eye Diseases That CanLead to Blindness: A Narrative Review. *Antioxidants (Basel)*. 2021 Mar 5;10(3):386. doi: 10.3390/antiox10030386. PMID: 33807538; PMCID: PMC8000043.

### GLAUCOMA (GLA)

1. Galbis-Estrada C, et al; Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplement with antioxidants and essential fatty acids; *Clin Int Aging* 2013;8:711-9
2. Tellez-Vazquez J, et al; Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenterstudy; *Clin Ophthalmol* 2016; 10:617-626.
3. Stéphanie Romeo; Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial. Communication Poster at Congress of European Glaucoma Society, Florence, May 20, 2018. Published in *Journal ofOphthalmology*, Volume 2018, Article ID 8259371, 8 pages; <https://doi.org/10.1155/2018/8259371>
4. Anton A, García V, Muñoz M, Gonzales K, Ayala E, Del Mar Sanchez E, Morilla-Grasa A. The Effect of Oral Citicoline and Docosahexaenoic Acid on the VisualField of Patients with Glaucoma: A Randomized Trial. *Life (Basel)*. 2022 Sep 23;12(10):1481. doi: 10.3390/1ife12101481. PMID: 36294916; PMCID:PMC9604833.

### EYE INFLAMMATION (EIN)

1. Pinazo-Durán MD, García-Medina JJ, Sanz-González SM, O'Connor JE, Casaroli-Marano RP, Valero-Velló M, López-Gálvez M, Peris-Martínez C, Zanón-Moreno V, Diaz-Llopis M. Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study.

1. Diagnostics (Basel). 2021 Apr 19;11(4):724. doi: 10.3390/diagnostics11040724. PMID: 33921773; PMCID: PMC8072877.
2. Peris-Martínez C, Piá-Ludeña JV, Rog-Revert MJ, Fernández-López E, Domingo JC. Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study. *Nutrients*. 2023 Mar 6;15(5):1300. doi: 10.3390/nu15051300. PMID: 36904299; PMCID: PMC10005296.

### TOPICAL EFFECT (TEF)

1. Pinazo-Durán MD, Raga-Cervera J, Sanz-González SM, Salgado-Borges J, Benítez-Del-Castillo J, Ramírez AI, Zanón-Moreno V. Efficacy and safety study of an eyelid gel after repeated nocturnal application in healthy contact lens users and non-users. *J Optom*. 2021 Jan-Mar;14(1):28-36. doi: 10.1016/j.optom.2019.12.002. Epub 2020 Apr 19. PMID: 32317229; PMCID: PMC7752988.

### CHILD CARE (CHC)

1. Rodríguez C, García T, Areces D, Fernández E, García-Noriega M, Domingo JC. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. *Neuropsychiatr Dis Treat*. 2019 May 8;15:1193-1209. doi: 10.2147/NDT.S206020. PMID: 31190827; PMCID: PMC6514260.
2. Ayats-Vidal R, Bosque-García M, Cordobilla B, Asensio-De la Cruz O, García-González M, Castro-Marrero J, López-Rico I, Domingo JC. Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. *J Clin Med*. 2023 May 26;12(11):3704. doi: 10.3390/jcm12113704. PMID: 37297899; PMCID: PMC10253750.
3. Ayats-Vidal R, Bosque-García M, Cordobilla B, Asensio-De la Cruz O, García-González M, Loureda-Pérez S, Fernández-López E, Robert-Barricocanal E, Valiente-Planas A, Domingo JC. Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. *Nutrients*. 2024 Mar 27;16(7):970. doi: 10.3390/nu16070970. PMID: 38613004; PMCID: PMC11013158.

### FERTILITY (FER)

1. Martinez-Soto JC; Effect of dietary DHA supplementation on sperm DNA integrity; *Fertility & Sterility* 2010; 94(4):S235-S236 P-495;
2. Popova A Yu, et al, Experience in the use of docosahexaenoic acid (BrudyPlus) in patients with increased sperm DNA fragmentation index in Acad. V.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology; *Andrology & Genital Surgery* 2015; 16(2): 51-55.
3. Vinogradov I.V., Gamidov S.I., Gabliya M.Yu., Zhukov O.B., Ovchinnikov R.I., Malinina O.Yu., Popova A.Yu., Chaly M.E., Bragina E.E., Zhivulko A.R.(2019). Docosahexaenoic Acid in the Treatment of Idiopathic Forms of Male Infertility. *Urology*, 2019(11):00–00. [DOI:<https://dx.doi.org/10.18565/urology.2019.16.00-00>].
4. Martinez-Soto JC, et al; Dietary supplementation with docosahexaenoic acid (DHA) improves seminal antioxidant status and decreases sperm DNAfragmentation; *Syst Biol Reprod Med*. 2016 Oct 28:1-9.

### SPORTS (SPO)

1. JF Guzman, et al; DHA- rich fish oil improves complex reaction time in female elite soccer players; *Journal of Sports Science and Medicine* (2011) 10, 301-305.
2. Francisco J. López-Román, et al; Effect of Docosahexaenoic acid supplementation on difference of endurance exercise performance in competitive andnon-competitive male cyclists; *Gazzetta Medica Italiana* 2019; 178(6):411-6.
3. Lydia de Salazar, et al; Oxidative Stress in Endurance Cycling Is Reduced Dose-Dependently after One Month of Re-Esterified DHA Supplementation; *Antioxidants* 2020, 9: 1145; doi:10.3390/antiox911145.
4. Domingo J. Ramos-Campo, et al; Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammation

- matory and MuscleDamage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial; *Nutrients* 2020, 12, 719; doi:10.3390/nu12030719.
5. Vicente Ávila-Gandía, et al; Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists; Accepted in *Journal of the InternationalSociety of Sports Nutrition* 2020. Comunicaciones relevantes/Tesis Doctoral:
6. José A. Villegas et al; Dep. Fisiología; Universidad Católica de San Antonio, Murcia; Protección del daño oxidativo en el DNA tras el ejercicio intenso;Comunicación presentada en el 30 Congreso Mundial de Medicina del Deporte; Barcelona, 18-23 Noviembre 2008.
7. Carlos J Contreras; Modification of the oxidative damage in a group of cyclists after consuming docosahexaenoic acid at different doses; Doctoral Thesis, Catholic University of Murcia, 2014.

### LIPID METABOLISM (LME)

1. Pere Domingo, et al; Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind,placebo-controlled study; *Clin Nutr*. 2018 Aug;37(4):1340-1347.
2. Pere Domingo, et al; Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infectedpatients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study; *Cytokine* 2018; 105:73-79.
- 3.ZoeBoyer-Díaz,etal;Anutraceuticalrichindocosahexaenoicacidimproves portal hypertension in a preclinical model of advanced chronic liver disease; *Nutrients* 2019; 11, 2358; doi: 10.3390/nu11102358. Reviews:
4. Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension:Potential of DHA as Nutraceutical. *Nutrients*. 2020 Aug 28;12(9):2627. doi: 10.3390/nu12092627. PMID: 32872239; PMCID: PMC7551786.
5. Mora I, Puiggròs F, Ferras F, Gil-Cardoso K, Escoté X. Emerging models for studying adipose tissue metabolism. *Biochem Pharmacol*. 2024May;223:116123. doi: 10.1016/j.bcp.2024.116123. Epub 2024 Mar 12. PMID: 38484851.

### OTHER THERAPEUTIC AREAS AND IN VITRO TESTS: NEUROLOGY

1. Mancera P, et al; Natural Docosahexaenoic Acid in the Triglyceride Form Attenuates In Vitro Microglial Activation and Ameliorates AutoimmuneEncephalomyelitis in Mice; *Nutrients* 2017, 9, 681; doi:10.3390/nu9070681.
2. Maricel Gómez-Soler, et al; Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism; *Frontiers inNeuroscience* 2018; 12: Article 604.
3. Mora I, Arola L, Caimari A, Escoté X, Puiggròs F. Structured Long-Chain Omega-3 Fatty Acids for Improvement of Cognitive Function during Aging. *Int J MolSci*. 2022 Mar 23;23(7):3472. doi: 10.3390/ijms23073472. PMID: 35408832; PMCID: PMC8998232.

### IN VITRO

1. Dolz-Marco R, Gallego-Pinazo R, Pinazo-Duran MD, Pons-Vázquez S, Domingo-Pedro JC, Díaz-Llopis M. Intravitreal docosahexaenoic acid in a rabbit model: preclinical safety assessment. *PLoS One*. 2014 May 8;9(5):e96872. doi: 10.1371/journal.pone.0096872. PMID: 24809445; PMCID: PMC4014583.
2. Mora I, Pérez-Santamaria A, Tortajada-Pérez J, Vázquez-Manrique RP, Arola L, Puiggròs F. Structured Docosahexaenoic Acid (DHA) Enhances Motility and Promotes the Antioxidant Capacity of Aged *C. elegans*. *Cells*. 2023 Jul 26;12(15):1932. doi: 10.3390/cells12151932. PMID: 37566010; PMCID: PMC10417004.
3. Mora I, Teixidó A, Vázquez-Manrique RP, Puiggròs F, Arola L. Docosahexaenoic Acid (DHA) Supplementation in a Triglyceride Form Prevents from Polyglutamine-Induced Dysfunctions in *Caenorhabditis elegans*. *Int J Mol Sci*. 2024 Nov 23;25(23):12594. doi: 10.3390/ijms252312594. PMID: 39684306; PMCID: PMC11640917.



▲  
See digital  
version



# BRUDYLAB QUALITY SCIENTIFICALLY SUPPORTED



CELLULAR OXIDATIVE  
DAMAGE PATENT



DYSLIPIDEMIA IN HIV  
PATENT



TUMORAL DISEASES  
PATENT



CLINICAL  
TRIALS



DHA WITH GUARANTEED  
BIOACTIVITY



DHA  
MADE IN EUROPE



CERTIFIED QUALITY  
ISO 9001



THIRD PARTY  
TESTED



SUSTAINABLE  
DHA



MEMBERS  
OF THE GOED



CONTAMINANT-FREE  
DHA



PLASTIC-FREE  
OIL



KOSHER  
DHA



HALAL  
DHA



GLUTEN-FREE  
DHA



LACTOSE-FREE  
DHA